<DOC>
	<DOCNO>NCT02648425</DOCNO>
	<brief_summary>This phase IB study ass safety tolerability ASLAN001 give combination either Cisplatin 5-Fluorouracil Cisplatin Capecitabine , view identify recommend Phase II dose .</brief_summary>
	<brief_title>Safety Tolerability ASLAN001 Combination With Cisplatin 5-FU Cisplatin With Capecitabine</brief_title>
	<detailed_description>This open-label , Phase I , dose escalation study ASLAN001 give combination Regimen A Regimen B , patient metastatic solid tumor , eligible receive cisplatin/5-fluorouracil cisplatin/capecitabine regimen . If study medication consider MTD , , ≥ 2 DLTs observe one cohort , next cohort receive ASLAN001 dose de-escalation combination chemotherapy . Dose ASLAN001 start 400mg BID ; , dose escalation 500mg BID dose de-escalation 300mg BID depend DLTs observe cohort . Regimen A : Depends preferred medical practice , Cohort 1A receive ASLAN001 400 mg BID combination cisplatin 80 mg/m2 IV infusion 5 fluorouracil 800 mg/m2/day IV infusion 5 day every 3 week ; receive ASLAN001 400 mg BID combination Cisplatin 35 mg/m2 24-hour infusion day 1 day 8 , 5-fluorouracil 2,000 mg/m2 Leucovorin 300mg/m2 24-hour infusion day 1 , day 8 day 15 every 4 week . Regimen B : Cohort 1B receive ASLAN001 400 mg BID combination cisplatin 80 mg/m2 IV infusion oral capecitabine 1,000 mg/m2 BID 14 day every 3 week .</detailed_description>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Male female patient 20 year age old time write informed consent obtain . 2 . Regimen A : Patients metastatic solid tumor eligible treatment cisplatin 5fluorouracil . The standard dose schedule cisplatin 5fluorouracil accord preference investigator institution . Regimen B : Patients metastatic solid tumor eligible treatment cisplatin combination capecitabine . 3 . Patients partial gastrectomy may allow participate study long take oral medication meet inclusion/exclusion criterion . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 5 . Adequate organ hematological function evidence follow laboratory study within 14 day prior enrolment : Hematological function , follow : Absolute neutrophil count ≥ 1.5 x 109/L . Platelet count ≥ 100 x 109/L . Hemoglobin ≥ 9 g/dL . Coagulation function , follow : Partial thromboplastin time activate partial thromboplastin time ≤ 1.5 x upper limit normal ( ULN ) per institutional laboratory normal range . International normalized ratio ≤ 1.5 . Renal function , follow : • Creatinine clearance ≥ 50 mL/min calculate CockcroftGault formula . Hepatic function , follow : Total bilirubin ≤ 1.5 x ULN . AST ALT ≤ 2.5 x ULN ( ≤ 5 x ULN liver metastasis present ) . 1 . Patients persistent gastric outlet obstruction , complete dysphagia feed jejunostomy . 2 . Patients receive proton pump inhibitor H2 antagonist establish , symptomatic gastro duodenal ulceration gastroesophageal reflux disease . 3 . Patients unresolved toxicity grade 2 prior anticancer therapy . 4 . Untreated symptomatic central nervous system metastasis . Patients history brain metastasis eligible definitive therapy administer ( surgery and/or radiation therapy ) , plan treatment brain metastasis , patient clinically stable corticosteroid least 2 week prior enrolment . 5 . Major surgical procedure within 28 day prior enrolment . 6 . Clinically significant cardiovascular disease symptomatic uncontrolled . 7 . Known positive test human immunodeficiency virus , hepatitis C , hepatitis B surface antigen . 8 . Pregnant breastfeeding female . 9 . Patients hear impairment , due potential ototoxicity cisplatin .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>ASLAN001</keyword>
</DOC>